Selected article for: "control prevention and diagnosis protocol"
Author: Jin, Zhe; Liu, Jing-Yi; Feng, Rang; Ji, Lu; Jin, Zi-Li; Li, Hai-Bo
Title: Drug treatment of coronavirus disease 2019 (COVID-19) in China.
  • Cord-id: rnj3wtg4
  • Document date: 2020_6_27
    • ID: rnj3wtg4
    Snippet: Since December 2019, the coronavirus disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread throughout China as well as other countries. More than 8,700,000 confirmed COVID-19 cases have been recorded worldwide so far, with much more cases popping up overseas than those inside. As the initial epicenter in the world, China has been combating the epidemic for a relatively longer period and accumulated valuable experience in prevention and cont
    Document: Since December 2019, the coronavirus disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread throughout China as well as other countries. More than 8,700,000 confirmed COVID-19 cases have been recorded worldwide so far, with much more cases popping up overseas than those inside. As the initial epicenter in the world, China has been combating the epidemic for a relatively longer period and accumulated valuable experience in prevention and control of COVID-19. This article reviewed the clinical use, mechanism and efficacy of the clinically approved drugs recommended in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (DTPNCP) released by National Health Commission of P.R.China, and the novel therapeutic agents now undergoing clinical trials approved by China National Medical Products Administration (NMPA) to evaluate experimental treatment for COVID-19. Reviewing the progress in drug development for the treatment against COVID-19 in China may provide insight into the epidemic control in other countries.

    Search related documents:
    Co phrase search for related documents
    • acute lung injury and low mortality: 1, 2, 3, 4, 5
    • acute lung injury and lung alleviate: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute lung injury and lung lesion: 1
    • acute lung injury and lymphocyte count: 1, 2, 3
    • lopinavir ritonavir and low mortality: 1, 2, 3, 4, 5, 6, 7, 8
    • lopinavir ritonavir and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • lopinavir ritonavir and lung lesion: 1, 2
    • lopinavir ritonavir and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • low mortality and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • low mortality and lung lesion: 1
    • low mortality and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • lung injury and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • lung lesion and lymphocyte count: 1, 2, 3, 4, 5, 6